- Home
- GDEV vs AVIR Comparison
GDEV vs AVIR Comparison
Compare GDEV & AVIR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GDEV
- AVIR
- Stock Information
- Founded
- GDEV 2009
- AVIR 2012
- Country
- GDEV Cyprus
- AVIR United States
- Employees
- GDEV N/A
- AVIR N/A
- Industry
- GDEV EDP Services
- AVIR Medicinal Chemicals and Botanical Products
- Sector
- GDEV Technology
- AVIR Health Care
- Exchange
- GDEV Nasdaq
- AVIR Nasdaq
- Market Cap
- GDEV 268.7M
- AVIR 273.7M
- IPO Year
- GDEV N/A
- AVIR 2020
- Fundamental
- Price
- GDEV $15.41
- AVIR $2.97
- Analyst Decision
- GDEV Buy
- AVIR Hold
- Analyst Count
- GDEV 2
- AVIR 1
- Target Price
- GDEV $70.00
- AVIR $6.00
- AVG Volume (30 Days)
- GDEV 27.1K
- AVIR 441.1K
- Earning Date
- GDEV 05-16-2025
- AVIR 05-12-2025
- Dividend Yield
- GDEV N/A
- AVIR N/A
- EPS Growth
- GDEV N/A
- AVIR N/A
- EPS
- GDEV 1.38
- AVIR N/A
- Revenue
- GDEV $420,933,000.00
- AVIR N/A
- Revenue This Year
- GDEV N/A
- AVIR N/A
- Revenue Next Year
- GDEV $12.39
- AVIR N/A
- P/E Ratio
- GDEV $11.17
- AVIR N/A
- Revenue Growth
- GDEV N/A
- AVIR N/A
- 52 Week Low
- GDEV $8.60
- AVIR $2.46
- 52 Week High
- GDEV $42.76
- AVIR $4.15
- Technical
- Relative Strength Index (RSI)
- GDEV 54.94
- AVIR 56.05
- Support Level
- GDEV $14.91
- AVIR $2.78
- Resistance Level
- GDEV $16.00
- AVIR $3.03
- Average True Range (ATR)
- GDEV 0.79
- AVIR 0.17
- MACD
- GDEV -0.11
- AVIR 0.03
- Stochastic Oscillator
- GDEV 42.71
- AVIR 88.03
About GDEV GDEV Inc.
GDEV Inc is a gaming and entertainment holding company that oversees a portfolio of studios focused on developing and publishing live-service games across a range of platforms and genres. Its portfolio includes studios specializing in mobile, browser, and PC games, as well as captivating IPs spanning various genres.
About AVIR Atea Pharmaceuticals Inc.
Atea Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing antiviral therapeutics to improve the lives of patients suffering from serious viral infections. The company is developing its product candidate, bemnifosbuvir, for the treatment of COVID-19, the disease caused by infection with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and its variants and also developing bemnifosbuvir in combination with ruzasvir for the treatment of Hepatitis C (HCV).